Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol.
Hyperuricemia
Non-alcoholic fatty liver disease (NAFLD)
Resveratrol (RES)
Silent information regulator 1 (SIRT1)
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
07
11
2018
revised:
03
12
2018
accepted:
07
12
2018
pubmed:
18
12
2018
medline:
19
4
2019
entrez:
18
12
2018
Statut:
ppublish
Résumé
Background Hyperuricemia is a recognised risk factor for the development of nonalcoholic fatty liver disease (NAFLD). This study aims to investigate the therapeutic effect of resveratrol (RES) on the treatment of hyperuricemia-related NAFLD in rats and the underlying mechanisms. Methods NAFLD with hyperuricemia was induced in rats using high-yeast high-fat diet containing potassium oxonate. The impact of RES on liver pathology, and the expression of silent information regulator 1 (SIRT1), fork-head box class O-3a (FOXO3a), and nuclear factor kappa B subunit p65 (NF-κB p65) was analysed. Results RES significantly improved liver histology and reversed serum biochemical abnormalities. At the molecular level, RES improved insulin resistance (IR), inhibited hepatic steatosis, reduced oxidative stress and liver inflammation, and these effects were likely mediated through SIRT1-mediated FOXO3a phosphorylation and NF-κB P65 deacetylation. Conclusions Resveratrol is a promising agent for the treatment of hyperuricemia-related NAFLD through activating SIRT1 pathways.
Identifiants
pubmed: 30557833
pii: S0753-3322(18)37898-3
doi: 10.1016/j.biopha.2018.12.039
pii:
doi:
Substances chimiques
Antioxidants
0
Resveratrol
Q369O8926L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
844-849Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Masson SAS.. All rights reserved.